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1. Introduction 
In recent decades, fungi have emerged as important causes of human infection, due 
primarily to the increased numbers of patients subjected to severe immunosuppression, so 
the demand for information on the pathogenic role of these microorganisms and the 
diseases they cause is growing.  
Despite the development of more active, less toxic antifungal agents and the use of 
antifungal prophylaxis, the mycoses (especially those invasive) continue to be a serious 
infective complication in several patients’ outcomes, resulting in high mortality rates 
(Lehrnbecher et al., 2010). Both paediatric and adult patients are exposed to fungal 
infections, even if important differences of epidemiology, diagnostic approaches and 
therapeutic management have to be considered. To date, globally, these infections have been 
well studied in different populations of adult patients while thorough epidemiological 
analyses in paediatric patients, including immunocompromised subjects, e.g. children with 
haematological malignancies and preterm neonates, are fairly sparse. 
1.1 General characteristics of fungi 
Fungi are ubiquitous organisms that live as environment saprophytes or as commensal 
microorganisms of humans and animals.  
They morphologically are distinguished in yeasts (unicellular organisms) and moulds 
(multicellular organisms). Most fungi are found in morphological organization as yeasts or 
moulds but some species, known as dimorphic fungi, can be found as yeasts or moulds 
depending on the temperature and substrate on which they develop. They grow in 
environment as moulds and in humans as yeasts.  
Of the more than 100,000 species of fungi identified to date, only few species can infect man 
and of them only a few are sufficiently virulent to infect a healthy host.  
On the basis of their pathogenic role, fungi can be divided into:  
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 primary pathogens (dimorphic fungi, such as Histoplasma, Blastomyces, Coccidioides) which 
can also infect immune-competent subjects. They are microorganisms endemic to 
America, Africa and Asia. 
 opportunistic pathogens (yeasts and moulds, such as Candida spp., Cryptococcus spp, 
Aspergillus spp, Zygomycetes and Fusarium spp) which can cause damage to the host if 
the immune system is compromised.  
According to the site of infection and degree of tissue involvement, fungi can cause 
superficial, cutaneous, subcutaneous and deep mycoses (Kern & Blenvins, 1997).  
The superficial mycoses are limited to the stratum corneum and essentially elicit no 
inflammation response; they are caused specially by fungi dermatophytes that produce 
keratinase and live on human keratin (skin, hair and nails). The cutaneous infections involve 
the integument and its appendages. The sub-cutaneous mycoses affect the subcutaneous 
tissues usually at the point of traumatic inoculation of the etiological agent. The deep 
infections involve systems and organs stimulating high immune response. The Table 1 
shows the classification of most fungal infections. 
 
Pattern of infection Fungal infection Etiological agent  
Superficial and 
cutaneous 
  
  
  
  
  
  
Pityriasis versicolor Malassetia furfur 
Tinea nigra Exophiala werneckii 
White piedra Trichosporon beigelii 
Black piedra  Piedraia hortae 
Dermatophytosis Microsporum spp 
Trichophyton spp 
Epydermophyton floccosum 
Candidiasis of skin, nail, mucosa Candida spp 
Sub- cutaneous 
  
  
Chromoblastomycosis Fonsecaea pedrosoi  
Phialophora verrucosa etc. 
Mycetoma  
 
 
 
Madurella mycetomatis  
Acremonium, Pseudallescheria, 
Exophiala, Curvularia, Fusarium, 
Aspergillus, etc. 
Sporotrichosis  Sporothrix schenckii  
Deep  by dimorphic 
fungi 
  
Blastomycosis  Blastomyces dermatitidis  
Coccidioidomycosis  Coccidioides immitis 
Histoplasmosis  Histoplasma capsulatum  
Paracoccidioidomycosis Paracoccidioides brasiliensis 
Deep  by opportunistic 
pathogen fungi 
  
  
Aspergillosis  Aspergillus spp  
Sistemic Candidiasis   Candida spp  
Cryptococcosis Cryptococcus neoformans/gattii 
Zygomycoses Rhizopus, Absidia, Mucor etc.  
Table 1. Classification of most fungal infections and their principal etiological agents.  
The deep mycoses are those of highest concern for the life-threatening consequences. They 
can be identified in: 
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Invasive Mycoses: deep fungal infection with predominant deep tissue invasion in the 
absence of blood dissemination.  
Disseminated Mycoses: deep fungal infection involving multiple organs or systems that do 
not touch each other and without being transported by blood or lymph.  
Systemic Mycoses: deep fungal infection confined to a single organ or system achieved by 
blood.  
Infecting fungi may be either exogenous or endogenous so, according to the route of 
acquisition, a mycoses  may be designated as exogenous or endogenous in origin.  
The moulds have their natural habitat in the environment so they always originate 
exogenous infections caused mainly by the inhalation of air widespread conidia . This kind 
of infections are often correlated to environmental contamination especially during 
construction works. Given the ubiquitous nature of fungal spores, in particular of Aspergillus 
spp, in the external environment, numerous sources have been identified also in hospitals: 
unfiltered air; conditioned air systems with poorly maintenance; persistent construction 
works. Therefore, the presence of Aspergillus spp in the hospital setting is the major extrinsic 
risk factor for the occurrence of nosocomial invasive aspergillosis mainly among 
neutropenic patients. 
On the contrary, the yeasts can be endogen and exogenous. The endogen yeasts colonize the 
mucosa and in particular conditions (immunocompromise, mucosite post-chemotherapy) 
can invade the organism and cause the disease. The exogenous yeasts are commensal of 
skin, they can invade the organism via percutaneum, such as parenteral nutrition or 
intravascular catheter contamined especially by the hands of health care workers. Many of 
these invasive mycoses are difficult to diagnose early, yet the patient’s outcome depends, 
other than restoration of host defences, on fast and correct etiological diagnosis and so on 
early and proper antifungal treatment. 
2. Paediatric patients at risk of fungal infection 
At the beginning century, fungal infections were quite rare, but in the last years the 
paediatric and adult populations at risk of mycoses continue to expand so also the spectrum 
of opportunistic fungal pathogens continue to increase.  
Even if both children and adults are exposed to these significant infections, important 
differences between the two populations are documented as predisposing factors and 
epidemiology.  
The main paediatric patients at risk of invasive fungal infections are pre-term neonates, 
children with congenital immune deficiencies, with acquired immune deficiencies 
associated with HIV infection, cancer and patients in treatment with corticosteroids or who 
have chronic destructive lung diseases.  
Generally, functional defects of phagocytes cells predispose to invasive infections by 
opportunistic fungi (Candida spp, Aspergillus spp, Fusarium spp), while alterations of T 
lymphocytes function are correlated to muco-cutaneous candidiasis and invasive infection 
by Cryptococcus neoformans. In addition, a large variety of non-immunological factors are 
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recognized as predisposing to fungal infection, such as the presence of intravascular 
catheter, Candida colonization, use of broad-spectrum antibiotics, parenteral nutrition and 
abdominal surgery (Table 2).  
Predisposing conditions, patterns of infection, etiological agents and therapeutic treatment 
are different among diverse paediatric populations.  
 
RISK FACTORS 
Immunological Non-immunological 
Functional defects of phagocytes cells Intravascular catheter 
Alterations of T lymphocytes function Candida colonization 
 
Use of broad-spectrum 
antibiotics 
Parenteral nutrition 
Abdominal surgery 
Table 2. Classification of some  immunological and non-immunological risk factors for 
invasive fungal infections. 
3. Neonate patients 
At birth, neonates can be colonized by Candida spp at the level of muco-cutaneous surfaces, 
so also healthy babies can have fungal oral thrush and diaper rash. The thrush is a typical 
Candida oral infection by the mouths of babies. It is caused generally by Candida albicans, and 
more rarely by Candida glabrata or Candida tropicalis. The infection can develop suddenly and 
appears as white plaques on mucosa of oral cave (including palate, tongue). In general, 
candidal trush does not cause fever and  the predisposing factors  are antibiotics therapy, 
corticosteroids (especially if inhaled). This infection can be treated with topical antifungal 
drugs, such as nystatin, miconazole, Gentian violet or amphotericin B. Gentian violet is a 
dye with antifungal activity that can be used for breastfeeding thrush, but its use is not 
recommended in large quantities because it can cause mouth and throat ulcerations in 
nursing babies.  
Yeast diaper rash is a reaction of the skin that can appear around anus, on the thighs, genital 
creases and the infected area is usually red and elevated. It is estimated that 15-20% of 
diaper rash are due to yeast and in particular to C. albicans.  
On the contrary of health babies, in pre-term and in critically ill neonates Candida spp is 
often the cause of life-threatening invasive infections. Generally, the incidence of invasive 
candidiasis is higher in the paediatric population than adult and with the higher risk in 
neonates. In critically ill neonates, Candida spp is the third most common agent of late-onset 
infections, with an incidence ranging from 2.6-10% among very low birth weight (1001-1500 
g) babies and from 5.5-20% among extremely low birth weight (<1000 g) infants (Benjamin 
et al., 2006; Chapman et al., 2007; Cotten et al., 2006; Levy et al., 2006). The crude mortality 
associated with these infections ranges from 15-30% and an attributable mortality of 6-22% 
despite appropriate therapy (Benjamin et al., 2006; Zautis et al.,2007) but these values can 
increase to 60% (Castagnola & Buratti, 2009). The high mortality rate can be related to the 
difficulty in making an early diagnosis. In fact, the reduced sensitivity of diagnostic tests, 
non-specific clinical signs and inadequate or delayed treatments can condition the outcome 
of patients (Brecht et al., 2009; Stronati & Decembrino, 2006). 
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Whereas in paediatric patients the risk factors may differ according to the underlying 
disease and the consequent specific immunodeficiency, in neonates the primary risk factors 
are prematurity and colonization. In particular Candida colonization, originating from the 
endogenous flora inhabiting the gastrointestinal tract, is considered a prerequisite for the 
development of invasive candidiasis. Manzoni et al. (Manzoni, et al., 2006) showed that 
Candida colonization in multiple body sites is an important predictor of progression to 
invasive mycoses, emphasizing the need of systematic surveillance cultures in the preterm 
infants. It is important to underline that the preterm infants are commonly infected by C. 
albicans and C. parapsilosis, the children aged younger than 1 year are infected most often by 
C. parapsilosis, while in the adolescents the incidence of C. glabrata exceeds that of C. 
parapsilosis (Sai et al, 2011). Besides,  C. albicans and C. parapsilosis are by a long time 
recognized as causative agent of infections related to the intravascular catheters and drains 
that can be  contaminated by the hands of health care workers (Velasco et al. 2011, Weems et 
al., 1986). The relatedness between the strains isolated from the patients and those isolated 
from the hands of health care workers, strongly suggests person to person transmission and 
supports the widely held view that the hands of personnel are the route of transmission of 
some Candida spp, in particular C. parapsilosis. Also Malassetia spp, a commensal lipophilic 
yeast that colonizes the human skin can cause systemic infection in premature babies. The 
transmission of infection is liable to contamination of vascular catheters by the hands of 
healthcare workers or contamination of intravenous solution (Chang et al., 2006; Oliveri et 
al., 2011).  
Recently Montagna et al. (Montagna et al., 2010) evaluated the epidemiology of invasive 
fungal infections among infants admitted to Neonatal Intensive Care in southern Italy by the 
multicenter surveillance “Aurora Project”. They observed that overall incidence was 1.3% 
and crude mortality was 23.8%. Infants weighing 1500 g (4.3% ) showed a significantly 
higher incidence than those 2500 g (0.2%). C. parapsilosis (61.9%) was the most frequent 
isolated species. The outcomes for neonates differ markedly from those in older patients. 
Even if the mortality is generally lower in neonates, they frequently have serious 
complications as meningoencephalitis. 
The neonatal patients rarely show the infections caused by filamentous fungi, such as 
Aspegillus and Zygomycetes, however they can cause skin infection after necrotizing skin 
lesions and gastrointestinal tract infection after mucositis induced by enterocolitis. The 
filamentous fungi infections are mainly correlated to contaminated water and ventilation 
systems (Abdul Salam et al., 2010; Robertson et al., 1997). The neonates admitted to intensive 
care units may be predisposed to aspergillosis because of their immature phagocytic 
capacity, the frequent administration of corticosteroids and prolonged hospitalization. In a 
study carried out by Groll et al. (Groll et al., 1998a) on the cases of aspergillosis documented 
in babies < 3 months of age, 32% had disseminated aspergillosis, 25% had primary cutaneus 
aspergillosis and 23% had invasive pulmonary aspergillosis. At least 41% of the patients had 
received corticosteroid therapy before diagnosis and only one patient had been neutropenic, 
while the prematurity was the major underlying condition (43%), only 14% had proven 
chronic granulomatous disease. Among different species of Aspergillus responsible for 
invasive aspergillosis, A. fumigatus was the species most frequently recovered in babies, 
followed by A. flavus , A. terreus and A. niger. 
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Regarding neonatal zygomycosis, poor data are available. Roileds et al. (Roileds et al., 2009) 
analyzed the documented cases in literature. The prematurity was a major underlying factor 
among neonatal cases, the most common manifestations of zygomycosis were 
gastrointestinal (54%) and cutaneous (36%) and the overall mortality was 64%.  
3.1 Children patients 
Although healthy children have strong natural immunity against fungal infections, some 
superficial mycoses such as Tinea frequently occur. Tinea, caused by dermatophyte fungi 
such as Trichophyton, Epydermophyton, Microsporum, is a skin infection that transmit by direct 
skin-to-skin contact with an infected person, or by contact with contaminated surface such 
as floors in shower and locker rooms (Andrews et al., 2008). The infection can involve the 
body in particular trunk, arms and leg, known as Tinea corporis; while Tinea capitis is a scalp 
infection, it is frequent among children of age 3–9 years that live in overcrowded areas; Tinea 
pedis is an infection of foot known as the athletes’ foot, it is acquired by walking barefoot on 
contaminated surface (including carpet, floors in shower) (Jain  et al., 2010). 
In children and adolescents with cancer the most important risk factors for fungal infections 
are the intravenous catheter, the mucositis induced by chemotherapy, broad spectrum 
antibiotics, and the therapeutic use of corticosteroids, especially in patients with acute 
leukaemia. Candida spp and Aspergillus spp are the most common etiological agents. In the 
neutropenic children, in particular in children with leukaemia or bone marrow 
transplantation, the frequency of the invasive candidiasis (candidemia, disseminated 
candidiasis etc.) is 8-10% with a crude mortality until to 100% in patients with persistent 
neutropenia or after hematopoietic stem cell transplantation (HSCT) (Castagnola et al. 2008; 
Finco  et al. 2011; Klingspor et al., 1997). 
Even if Candida albicans is recognized as the most common agent of such infections, other 
species are progressively increasing, such as Candida glabrata, Candida parapsilosis, Candida 
krusei and Candida tropicalis. In many locations in USA, in Asia and Latin America, C. 
glabrata, after C. albicans, is the second most frequent species, while in Europe C. parapsilosis 
is the most prevalent. Candida parapsilosis is a commensal of human skin and often causes 
exogenous systemic infection related to i.v. catheter use (Barchiesi  et al., 2004; Velasco et al. 
2011). Candida parapsilosis, as well as C. albicans, can form a biofilm on the plastic surface of 
the catheter so it becomes a continuative source of infection. In this regard the Infectious 
Diseases Society of America (IDSA) guidelines recommend removing the catheter, if at all 
possible (Pappas et al., 2009). In general the catheter removal is associated with shorter 
duration of candidemia and reduced mortality in neonates, adults and neutropenic patients, 
although the management of intravascular catheters in these subjects with candidemia is 
more complicated than with others. As it is observed in adult patients, the therapy with 
corticosteroids is one of the most frequent features that increase the risk of fungal infection 
in children immunocompromised for solid organ transplantation, engraftment after bone 
marrow transplantation or for immunological disorders (Fonseca et al., 2006). 
Other than Candida spp infections, in immunocompromised children Aspergillus spp 
infections are also documented. Aspergillus spp can cause invasive, saprophytic or allergic 
diseases. The saprophytic affliction includes Aspergillus spp otomycosis and pulmonary 
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aspergilloma; the allergic conditions include allergic sinusitis and allergic bronchopulmonary 
aspergillosis (APBA). APBA is a hypersensitivity disease of the lungs associated with 
inflammatory destruction of airways in response to Aspergillus spp. It can increase for clinical 
stages of asthma managed with corticosteroid for a long time. It can be defined through 
primary diagnostic criteria (episodic bronchial obstruction, asthma, peripheral eosinophilia, 
elevated serum IgE concentrations, central bronchiectasis) and secondary diagnostic criteria 
(repeated detection of Aspergillus spp in sputum samples, Arthus reaction -late skin reactivity- 
to Aspergillus antigen) (Walsh et al., 2008). ABPA also affects a significant proportion of cystic 
fibrosis patients because of prolonged colonization with Aspergillus spp, this fact has been 
associated with accelerated deterioration of lung function.  
The invasive aspergillosis (IA) represents an important cause of morbidity and mortality in 
children with haematological malignancies or those undergoing bone marrow 
transplantation. In fact its frequency is estimated to be 4.5-10% with crude mortality of 40-
94% (Steinback, 2005a). The Antimicrobial Availability Task Force (AATF) of the Infectious 
Diseases Society of America has identified Aspergillus spp among the particularly 
problematic pathogens for which an early treatment is urgently needed, together with other 
microorganisms, such as Acinetobacter baumannii, ESBL–producing Enterobacteriaceae, 
vancomycin-resistant Enterococcus faecium (VRE), Pseudomonas aeruginosa, and methicillin 
resistant Staphylococcus aureus (MRSA) (Talbot et al., 2006). IA is typical of neutropenic 
patients and it is usually absent in children in treatment for solid tumours. The most 
frequent species are A. fumigatus, A. flavus and A. terreus. The infection occurs by inhalation 
of conidia, of about 2-5 microns in size, small enough to be inhaled and deposited in the 
lungs of immunocompromised patients, in particular, of subjects exposed to prolonged and 
severe neutropenia. To date, it is not yet well defined what is the concentration of conidia 
that exposes the patient to risk of infection, especially for child patients. The concentration 
of spores in the air depends on several factors: weather, winds, seasonal factors, type of 
vegetation. So because of the ubiquitous spread of Aspergillus spp, environmental control 
measures, especially in the presence of construction works, are necessary to prevent 
infections in hospitals. In this regard, to avoid these fungal infections, some prevention 
measures are needed, such as: 
 high efficiency filters (High-Efficiency Particulate Air: HEPA) (Cornet et al., 1999); 
 horizontal laminar flow systems (Laminar Air Flow: LAF) (Barnes & Rogers, 1989), 
although the protection conferred by the LAF systems is still debated; 
 hospital rooms with positive pressure (Humphreys, 2004). 
In according to the European Organization for Research and Treatment of Cancer/Mycoses 
Study Group (EORTC/MSG) (De Paw et al, 2008) the diagnosis of invasive fungal infection 
can be classified as proven, probable and possible. It is considered proven when a 
histopathological documentation of infection and a positive result of culture of a specimen 
from a normally sterile site are available. It is defined probable when there are existing host 
factors, clinical manifestations (symptoms, signs and radiological features) and 
microbiological evidence; it is defined possible when there are only existing host factors and 
clinical manifestations. Early initiation of antifungal therapy in patients with strongly 
suspected invasive aspergillosis is required while a diagnostic evaluation is conducted 
(Cornely et al., 2007; Greene et al., 2007). With regard to aspergillosis, in addition to children 
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with haematological malignancy, children with primary immunodeficiency, chronic 
granulomatous disease and cystic fibrosis, are at high risk of IA (Steinbach, 2005a). 
4. Laboratory diagnosis of fungal infection 
One of the most difficult challenges of medical mycology is still the early initiation of an 
effective antifungal therapy to improve the outcome of patients, especially if affected by 
deep mycoses, but this fact is strongly related to a fast and proper etiological diagnosis. 
Despite the scientific progress and newer available diagnostic tools, the fungal infection 
diagnosis is still complex. Actually, the microscopic and cultural investigations remain the 
gold standard of mycological diagnosis, even if it is difficult to obtain appropriate 
specimens, the cultures have long duration and often the results are negative. In fact, in 
neonates with candidemia, the blood cultures have difficulty in providing positive results 
because only a small quantity of blood can be taken. Besides, blood cultures result positive 
for Candida spp only in 24-60% of cases and the fungal strains  grow slowly (Connell et al., 
2007; Montagna et al., 2009), this fact is incompatible with an early diagnosis.  
Besides the serological assays results are difficult to interpret because, for example, the 
circulating antibodies to Candida spp may occur in healthy subjects for the colonization of 
mucosal surfaces and their production in the immunocompromised patients can vary 
according to immune status (Ellepola & Morrison, 2005).  
Although, in neonatal patients the detection of mannan antigen, it is an antigen of 
membrane of Candida spp can show a sensitivity and specificity of 94.4% and 94.2% 
respectively, repetitive sampling is required because of the transient nature of mannan 
antigen. Besides, the literature data report a very low sensitivity of the Candida antigen test 
in patients with C. parapsilosis infection (Oliveri et al., 2008; Montagna et al., 2011a). In recent 
years, other important serum markers have been studied, such as the 13-β-D-glucan 
(BDG), so it has been included among the relevant diagnostic criteria by the European 
Organization for Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) 
(De Pauw et al., 2008). BDG is a component of the cell wall of a wide variety of fungi except 
for zigomycetes and Cryptococcus spp (Mancini et al., 2010; Odabasi et al., 2006). This test has 
been studied in adult patients, while in paediatric population only a few reports in 
particular describe the clinical relevance of BDG in preterm infants or onco-haematological 
paediatrics, yet this test seems to be very promising especially for the diagnosis of invasive 
candidiasis (Mularoni et al., 2010). However, it is important to consider that glucan is 
ubiquitous in the environment, so some medical sources of BDG can lead to a false positive 
result in the absence of deep mycoses: dialysis membranes and filters made from cellulose, 
cotton gauze employed during surgery, specific fractionated blood products, such as serum 
albumin and immunoglobulins, are reported to contain BDG, as well as exposure to some 
antitumor polysaccharides and certain parenteral antimicrobials (Chandrasekar, 2010; Marty 
et al., 2006). Montagna et al. (Montagna et al., 2011a) evaluated the performance of the BDG, 
individually and in comparison with the Candida mannan antigen, in preterm infants and 
onco-haematological paediatric patients with Candida BSI already proven by positive 
culture. The serum levels of BDG resulted positive on the same day as one positive blood 
culture in all examined patients, while Candida mannan antigen was negative in a child with 
C. albicans BSI and in all patients with C. parapsilosis fungemia. 
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Generally, in adults patients, the diagnosis of invasive pulmonary aspergillosis avails of 
radiology and galactomannan assay, on the contrary in the paediatric population the 
subjects with invasive pulmonary aspergillosis do not exhibit a “halo” sign and the 
galactomannan test specificity and sensitivity are very low. Galactomannan is a 
polysaccharide found within the cell wall of Aspergillus spp. It is released into the 
extracellular fluids (serum, urine, bronchoalveolar lavage, cerebrospinal fluid and other 
specimens) during hyphal growth and cell wall turnover. The detection of galactomannan in 
serum have been approved by the US Food and Drug Administration and have been 
included in the consensus criteria for diagnosis of invasive fungal infections (De Pauw et al., 
2008). In a study, overall positive predictive value  of galactomannan was calculated to be 
92.1% for adult HSCT recipients and 15.4% for children (Herbrecht et al., 2002). The 
specificity of this test may be compromised during therapy with some antibiotics, such as 
piperacillin-tazobactam, amoxicillin or amoxicillin with clavulanic acid, because these drugs 
contain the galactomannan so lead to false positive results. Besides, often the neonates are 
colonized in the intestinal tract by Bifidobacterium bifidum that may interfere with the 
galactomannan test and load the false-positive test, as well as the food or water containing 
galactomannan (Mennink-Kersten et al., 2004).  
The table 3 shows the advantage and disadvantage of major diagnostic methods. 
 
METHODS ADVANTAGES DISADVANTAGES 
Cultural investigations Golden standard 
Accurate  
Specific 
Fungi strains grow slowly 
 Needs of invasive techniques to 
obtain appropriate specimen  
Results may be falsely negative 
Galactomannan test High specificity  
Non-invasive 
 
Possible false-positives/ 
Possible false-negatives 
13-β-D-glucan test  
Non-invasive 
High negative-predictive 
value for most fungi 
 
Possible false-positives 
Candida mannan antigen 
 
Non-invasive 
Sensitivity 
Specificity 
Transient nature 
Very low sensitivity in C. 
parapsilosis infection 
 Possible false-positives 
Polymerase chain 
reaction 
Identification 
 genus /species 
High specificity 
Not standardized 
 Not commercially available 
Table 3. Advantages and disadvantages of major diagnostic methods. 
Another possible marker of invasive fungal infections is the Procalcitonin (PCT), a 116-amino 
acid protein synthesized in the C cells of the thyroid gland. It is virtually undetectable in 
healthy subjects (<0.5 ng/mL), but its concentration may increase up to 1000 ng/mL in 
patients with systemic bacterial infections or septic shock. Some authors have considered the 
PCT value as a potential biological marker of fungal sepsis (Christofilopoulou et al., 2002; 
Charles et al., 2009; Martini et al., 2010), but to date its role in diagnosis of these diseases has 
www.intechopen.com
 
Contemporary Pediatrics 394 
not yet been elucidated. In particular, the newborns may exhibit elevated PCT levels because 
of a physiological increase in the first days of life perhaps caused by birth trauma or host 
response to the initial establishment of the normal intestinal bacterial flora, but 3–4 days after 
birth the PCT levels revert to normal (Montagna, et al. 2011b; Turner et al., 2006).  
Several molecular methods have also been described for the diagnosis of opportunistic 
mycoses. However, they have not been standardized and have only been used in 
experimental cases, in the study of phylogenesis or for epidemiological purposes to 
investigate an epidemic cluster (Wise et al., 2007). The low application of this method in 
routine investigations can be explained with the very high sensibility of PCR methods (up to 
10 fg of nucleic acid, equivalent to 1-10 cells), so it is difficult to distinguish the fungal 
colonization or contamination from the real infection.  
5. Antifungal therapy 
Whilst several antibiotics are available, the number of antifungal drugs is relatively low. The 
slow progress in discovering new drugs could be elucidated by the fact that fungi are 
eukaryotic cells like mammalian cells, so the antifungal agents that have as target the 
biosynthesis of protein, RNA or DNA, result in being toxic for humans, especially at the 
level of liver and kidney. Nevertheless, over recent decades the number of antifungal agents 
has increased and new molecules with new mechanisms of action have been discovered, 
such as Echinocandins that act on the cell wall of the fungi. Although, today we have several 
therapeutic options, the treatment of deep mycoses in the paediatric population is still 
limited (Steinbach, 2005b; Zautis, 2010). 
To date four major categories of antifungal agents are available in clinical use: Polyenes, 
Azoles, Fluoro-pyrimidines  and Echinocandins. Some of these molecules have existed for a 
long time; others have been introduced into clinical practice only recently (i.e. caspofungin , 
posaconazole or voriconazole) (Table 4). 
The Polyenes are fungicidal drugs with a broad spectrum of activity against the most 
common yeasts and moulds, even if Aspergillus terreus, Aspergillus versicolor, Aspergillus 
lentulus, some strains of Aspergillus flavus, Scedosporium spp and C. lusitaniae result in being 
resistant. These drugs integrate with ergosterol of membranes and form the channels trans-
membrane that, increasing the permeability, cause leakage of cytoplasmic contents and cell 
death. This class includes Nystatin and Amphotericin B (AmB).  
Nystatin is used to treat cutaneous, vaginal, mucosal infections caused by Candida spp and it 
may be given orally as well as applied topically. In the UK its licence for treating neonatal 
oral thrush is restricted to those over the age of one month. 
Amphotericin B is available other than in deoxycholate formulation (D-AmB), in three lipid 
formulations  (LFAmBs) approved for use in humans: AmB lipid complex (ABLC), colloidal 
dispersion (ABCD), and in liposome (L-AmB). The lipid formulations are licensed for patients 
with invasive mycoses refractory or intolerant of D-AmB, in fact the infusion related reactions 
and nephrotoxicity often limit therapy with D-AmB. However, D-AmB at dosage of 1 mg/kg 
daily is recommended for neonates with disseminated candidiasis. If the urinary tract is not 
involved, L-AmB can be used at the dosage of 3–5 mg/kg daily. Even if not actually licensed, 
LFAmBs are frequently used as the first-line therapy for treatment of invasive aspergillosis, 
invasive candidiasis and zygomicosis (Cornely et al., 2007; Kuse et al., 2007).  
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CLASS AND 
COMPOUND 
MECHANISM OF ACTION  CLINICAL USE 
POLYENES Integrate with ergosterol of 
membrane and form the channels 
trans-membrane causing leakage of 
cytoplasmic contents and cell death 
 
      Amphotericin B  Invasive aspergillosis, 
invasive candidiasis and 
zygomycosis 
      Nystatin  Nongenital muco-cutaneous 
candidiasis, oro-pharyngeal  
candidiasis. In the UK the 
licence for treating neonatal 
oral thrush is restricted to 
those over the age of one 
month. 
AZOLES Interact with cytochrome P-450, 
during the biosynthesis of ergosterol 
at the step of synthesis by lanosterol 
to ergosterol, causing ergosterol 
depletion and accumulation of sterols 
in the membrane 
 
      Econazole 
 
 inea, pityriasis versicolor 
      Ketoconazole   Superficial infections such as 
athlete's foot, ringworm, 
candidiasis  
      Fluconazole 
 
 
 Secondary treatment of 
invasive candidiasis; 
prophylaxis in neonates 
whose birth weight is 
<1000g. 
     Itraconazole   Invasive aspergillosis in 
patients who are refractory 
to standard therapy and in 
patients with ABPA  
     Miconazole  
 
 
 Superficial infections 
(athlete's foot, ringworm), 
oral or vaginal thrush, lip 
disorder angular cheilitis. It 
is used in  treatment of 
neonatal oral thrush. It  is an 
alternative to nystatin for 
babies of age under one 
month. 
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CLASS AND 
COMPOUND 
MECHANISM OF ACTION  CLINICAL USE 
     Posaconazole   Recommended for prevention 
of invasive aspergillosis in 
neutropenic patients with 
haematological disease; active 
also against Zygomycetes 
....Voriconazole   Primary  treatment of invasive 
aspergillosis; prevention of 
invasive aspergillosis in 
neutropenic patients  
FLUORO-PYRIMIDINES Inhibits  the biosynthesis of both RNA 
and DNA 
 
      5-Flucytosine   Rarely administered as a 
single drug, usually given in 
combination with AmB for 
patients with invasive 
diseases, such as Candida 
endocarditis or meningitis. 
ECHINOCANDINS Inhibit  beta 1, 3 D-glucan, block the 
formation of cell wall of fungi 
 
         Anidulafungin 
    
 In neonatal candidiasis 
should be used with caution 
and limited to situations in 
which resistance or toxicity 
precludes the use of 
Fluconazole or AmB 
       Caspofungin  In neonatal candidiasis 
should be used with caution 
and limited to situations in 
which resistance or toxicity 
precludes the use of 
Fluconazole or AmB 
      Micafungina   Approved as first-line 
therapy against invasive and 
oropharyngeal candidiasis 
in the newborn and older 
children 
Table 4. Mechanisms of action of some antifungal agents and their utility in clinical practice. 
The Azoles have fungistatic activity and take effect against major yeasts and filamentous 
fungi. They inhibit the enzymes necessary to convert lanosterol to ergosterol, causing 
ergosterol depletion and accumulation of sterols in the membrane. The disruption of the 
structure and many functions of membrane lead to inhibition of fungal growth. 
This class includes a major number of molecules. Some drugs are used for the treatment of 
superficial and cutaneous infections such as Miconazole that is mainly used externally for 
the treatment of superficial infections (athlete's foot, ringworm) and  for treatment  of oral or 
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vaginal thrush, for the lip disorder angular cheilitis. It is used in  treatment of neonatal oral 
thrush and it can be an alternative to nystatin for babies of age under one month. 
Econazole is used to treat skin tinea, pityriasis versicolor; ketoconazole is usually prescribed 
for topical infections such as athlete's foot, ringworm, candidiasis. 
The azoles principally used in invasive mycoses are Fluconazole, Itraconazole, Posaconazole 
and Voriconazole.  
Fluconazole is rapidly cleared in children, so the daily dose is doubled from 6 to 12 mg/kg 
for children of all age and neonates. Fluconazole can be used for Neonatal Candidiasis as an 
alternative to treatment with AmB, besides prophylaxis with Fluconazole may be 
considered in neonates whose birth weight is <1000 g (Manzoni et al., 2011).  
Itraconazole is used for treatment of invasive aspergillosis in patients who are refractory to 
standard therapy. In  combination with corticosteroids, it is recommended for the treatment 
of allergic bronchopulmonary aspergillosis while there are few data that examine the use of 
Itraconazole in the treatment of invasive candidiasis.  
Posaconazole is recommended for prevention of invasive aspergillosis in neutropenic 
patients with haematological disease and is active also against zygomycetes. Posaconazole is 
not indicated for paediatric age.  
Voriconazole is approved by FDA for the primary treatment of invasive aspergillosis, and 
has also been proven effective against Fusarium spp and Scedosporium apiospermum, it is the 
first and only drug ever specifically indicated for their treatment by the FDA. Voriconazole 
is licensed for children over 2 years old. 
The class of Fluoro-pyrimidines only represents the 5-Fluoro cytosine, a molecule that 
inhibits the biosynthesis of both RNA and DNA. Very low birth weight neonates may 
accumulate high plasma concentrations because of poor renal function due to immaturity, 
thus, the use of flucytosine needs careful monitoring of serum drug levels in this group of 
patients. The role of flucytosine in neonates with Candida meningitis is questionable and is 
not routinely recommended (Benjamin et al., 2006). Besides, rapidly the strains can develop 
resistance to flucytosine, so it is rarely administered as a single agent, but usually in 
combination with AmB for patients with invasive diseases. 
The Echinocandins are the newer antifungal drugs. 1,3 beta–D-glucan and block the 
formation of the cell wall of the fungi, but some strains such as Candida guilliermondii and 
Candida parapsilosis, Zygomycetes, Cryptococcus, Trichosporon, Fusarium and Scedosporium are 
intrinsically less sensitive or even resistant. This class includes Anidulafungin, Caspofungin 
and Micafungin, they are available only as parenteral preparations. Echinocandins should 
be used with caution in treatment of neonatal candidiasis and generally limited to situations 
in which resistance or toxicity precludes the use of Fluconazole or AmB. Micafungin is the 
only drug that has been authorized for by the EMA (European Medicines Agency) (Manzoni 
et al, 2011) and approved as first-line therapy against invasive and oropharyngeal 
candidiasis in the newborn and older children, it has recently been introduced into clinical 
onco-haematology Practice (Mikulska & Viscoli, 2011).  
To date the resistance to the antifungal agents most commonly used in clinical practice is 
relatively rare, nevertheless the frequent use of antifungal drugs as prophylactic in long-
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term treatments or empiric and pre-emptive therapy, might select resistant strains. In 
general the opportunistic fungi have variable susceptibilities to currently available 
antifungal drugs. For example Candida krusei is intrinsically resistant to Fluconazole, Candida 
glabrata is less susceptible than other Candida species, Candida lusitaniae and Aspergillus 
terreus are resistant to AmB, thus the need for prompt identification at level of genera and 
species and in vitro susceptibility testing is more and more pressing. 
The Clinical and Laboratory Standards Institute (Clinical and Laboratory Standards 
Institute, 2008a, Clinical and Laboratory Standards Institute, 2008b) has developed a 
reference microdilution broth method for antifungal susceptibility testing of yeasts and 
moulds, but it is not easy for routinely use in the clinical laboratory. Alternatively, more 
simplified and efficient approaches also have been developed such as YeastOne 
Colorimetric Antifungal plate and E-test. At regarding, it is important to underline that 
antifungal susceptibility testing have some limitations as an imperfect clinical correlation, so 
the drug susceptibility in vitro does not guarantee clinical success or failure. 
In every case, the proper antifungal treatment and the patient’s outcome depend on an 
accurate identification of the aetiological agent at the level of genera and species. In fact, 
although in recent years some fungal strains have become resistant to common drugs, 
generally the susceptibility of fungi to the currently available antifungal agents is 
predictable if the species of the infecting isolate is known (Pappas et al., 2009). However, to 
know the susceptibility in vitro and the local epidemiology of drug resistance can help the 
clinicians to choose the most appropriate therapy and therefore to guide the management of 
fungal infection. 
6. Conclusion  
Despite recent advances in diagnostic field and the current armamentarium of antifungal 
agents with widespread use of prophylaxis in high-risk groups, the mycoses (especially the 
deep mycoses) are yet a persistent public health problem of difficult management 
particularly in pediatric age. In these patients the epidemiology of fungal infections is 
complex and different in various ages, for example: in the children the risk factors may 
differ according to the specific pathology of the base and the consequent specific 
immunodeficiency while in neonates the primary risk factors are prematurity and 
colonization; some drugs are licensed only for children of age > 2 years etc.  
To date these fungal infections have been well studied in different populations of adult 
patients while a thorough analyses of predisposing factors, diagnostic methods and 
therapeutic options in pediatric age have not been well described. Infact, several studies 
have been carried out to know the fungal infections and improve the patients’ outcome, but 
most of them have exclude the pediatirc population. This fact has limited the knowledge of 
the epidemiology and management of pediatric fungal disease, so  we often extrapolate from 
adult data, information for children and neonates. Therefore, diagnostic tests standardized for 
adult patients or antifungal therapies licensed for adults are often used improperly in pediatric 
age .The future hope of medical science is to have new tools to improve the immune system of 
immunocompromised patients to control the opportunistic infections. Besides, the most 
difficult challenge of medical mycology is still the early initiation of an effective antifungal 
therapy to improve the patient’s outcome, so it is essential to have a fast and proper 
aetiological diagnosis. In addition, because studies among the paediatric populations affected 
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by fungal infections are few, it would be important in the future that clinical and laboratory 
investigations are focused in tandem on fungal infections in  pediatric age to have an optimal 
diagnoses and appropriate antifungal treatment. 
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